Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study

被引:1
|
作者
Lee, Ji Yun [1 ]
Lee, Ju-Hyun [1 ]
Seo, Jeongmin [1 ]
Kang, Minsu [1 ]
Jung, Eun Hee [1 ]
Kim, Sang-A [1 ]
Suh, Koung Jin [1 ]
Kim, Ji-Won [1 ]
Kim, Se Hyun [1 ]
Lee, Jeong-Ok [1 ]
Kim, Jin Won [1 ]
Kim, Yu Jung [1 ]
Lee, Keun-Wook [1 ]
Kim, Jee Hyun [1 ]
Lee, Jong Seok [1 ]
Bang, Soo-Mee [1 ]
机构
[1] Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Coll Med, Dept Internal Med, Gumi Ro 173 Beon Gil, Seongnam 13620, South Korea
关键词
Multiple Myeloma; Skeletal-Related Events; Korean; Incidence; Risk Factors; BONE; HEALTH; COMPLICATIONS; SURVIVAL; DISEASE;
D O I
10.3346/jkms.2024.39.e175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Realworld data regarding SREs in MM are limited. Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018. Results: Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8-58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2-25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs. During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use. Conclusion: This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Pharmacologic Prevention of Skeletal-related Events in Cancer Patients
    Bottiglieri, Sal
    Adams, Val
    ORTHOPEDICS, 2010, 33 (08) : 577 - 580
  • [42] Health resource utilization associated with skeletal-related events: results from a retrospective European study
    Jean-Jacques Body
    João Pereira
    Harm Sleeboom
    Nikos Maniadakis
    Evangelos Terpos
    Yves Pascal Acklin
    Jindrich Finek
    Oliver Gunther
    Guy Hechmati
    Tony Mossman
    Luis Costa
    Wojciech Rogowski
    Hareth Nahi
    Roger von Moos
    The European Journal of Health Economics, 2016, 17 : 711 - 721
  • [43] Health resource utilization associated with skeletal-related events: results from a retrospective European study
    Body, Jean-Jacques
    Pereira, Joao
    Sleeboom, Harm
    Maniadakis, Nikos
    Terpos, Evangelos
    Acklin, Yves Pascal
    Finek, Jindrich
    Gunther, Oliver
    Hechmati, Guy
    Mossman, Tony
    Costa, Luis
    Rogowski, Wojciech
    Nahi, Hareth
    von Moos, Roger
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (06): : 711 - 721
  • [44] Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark
    Annette Ø Jensen
    Jacob B Jacobsen
    Mette Nørgaard
    Mellissa Yong
    Jon P Fryzek
    Henrik T Sørensen
    BMC Cancer, 11
  • [45] Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark
    Jensen, Annette O.
    Jacobsen, Jacob B.
    Norgaard, Mette
    Yong, Mellissa
    Fryzek, Jon P.
    Sorensen, Henrik T.
    BMC CANCER, 2011, 11
  • [46] Update on the Pharmacological Prevention of Skeletal-related Events in Cancer Patients
    Kennedy, Kenneth
    Patel, Hetalkumari
    ORTHOPEDICS, 2011, 34 (12) : 982 - 985
  • [47] The cost of treating skeletal-related events in patients with prostate cancer
    Lage, Maureen J.
    Barber, Beth L.
    Harrison, David J.
    Jun, Sun
    AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (05): : 317 - 322
  • [48] Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study
    Cetin, Karynsa
    Christiansen, Christian Fynbo
    Jacobsen, Jacob Bonde
    Norgaard, Mette
    Sorensen, Henrik Toft
    LUNG CANCER, 2014, 86 (02) : 247 - 254
  • [49] Skeletal-related events in urological cancer patients with bone metastasis: A multicenter study in Japan
    Yokomizo, Akira
    Koga, Hirofumi
    Shinohara, Nobuo
    Miyahara, Tsukasa
    Machida, Noriko
    Tsukino, Hiromasa
    Uozumi, Jiro
    Nishiyama, Kenryu
    Satoh, Fuminori
    Sakai, Hideki
    Naito, Seiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (04) : 332 - 336
  • [50] Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data
    Kim, Christopher
    Bhatta, Sumita
    Cyprien, Lori
    Fonseca, Rafael
    Hernandez, Rohini K.
    JOURNAL OF BONE ONCOLOGY, 2019, 14